‘Expensive’ Hepatitis C drug with 95% cure rate soon to be available on prescription

Source: thinkSPAIN

September 25,2014

SPAIN’S health ministry has reached an agreement with the drug company which manufactures the only known cure for Hepatitis C in order to be able to offer it to patients free of charge.

The drug Sofosbuvir, retailed under the brand name Sovaldi, has a 95% cure rate but the pharmaceutical corporation in Germany wanted to charge 60,000 euros for each course of the medication.

This meant is has been prohibitively expensive and Spain has been unable to provide it on the national health system, meaning doctors could not prescribe it to patients infected with Hepatitis C.

But minister Ana Mato (pictured) has managed to agree a price which would make it affordable for Spain’s public funds, and expects the drug to be available on the health service byWednesday next week, October 1.

According to the World Health Organisation (WHO), viral hepatitis is one of the most serious illnesses on the planet and claims around 1.4 million lives a year.

It is estimated that in Spain, as many as 75% of Hepatitis C sufferers do not know they have the disease.

Experts believe that at least half of all Hepatitis C sufferers will have liver cirrhosis by the year 2030.

Mato was driven in her quest to make the medication available after a patient, José Manuel Culebras, who is in the later stages of liver degeneration caused by Hepatitis C, raised a petition on the campaign site Change.org.

He said he is ‘thrilled’ with the news that the drug will soon be available.

This entry was posted in Compassionate use, Hepatitis C, Pricing, WHO and tagged . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s